NCT00006208Unknown3 期
A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine Within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naive HIV-1 Infected Patients
适应症
相关药物
试验速览
- 阶段
- 3 期
- 试验地点
- 63
研究概览
简要总结
The purpose of this study is to compare the safety and effectiveness of emtricitabine and stavudine when given with didanosine plus efavirenz to HIV-infected patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be eligible for this study if they:
- •Are at least 18 years old at the time of screening.
- •Have plasma HIV-1 RNA loads (level of HIV in your blood) of 5,000 or more copies/ml at the time of screening.
- •Have not used any anti-HIV therapy for more than 2 days.
- •Have a negative pregnancy test within 22 days of starting study drugs.
- •Can be reached by telephone.
排除标准
- •Patients will not be eligible for this study if they:
- •Are pregnant or breast-feeding.
- •Use alcohol or illegal drugs that, in the opinion of the principal investigator, may interfere with the patient's ability to follow the dosing schedule and protocol evaluations.
- •Are being treated for active tuberculosis.
- •Are using astemizole, cisapride, midazolam, triazolam, ergot derivatives, St. John's wort, or drugs for a mental disorder.
- •Have a history of a serious mental disorder.
- •Are unwilling to use an effective barrier method of birth control during the study (for women who can get pregnant).
- •Have a history of opportunistic infections and cancers (Mycobacterium avium complex, cytomegalovirus, toxoplasmic encephalitis or disseminated toxoplasmosis, cryptosporidiosis, Isospora belli, progressive multifocal leukoencephalopathy, visceral Kaposi's sarcoma, and lymphoma). Patients with past episode of pulmonary tuberculosis, Pneumocystis carinii pneumonia, or isolated cutaneous Kaposi's sarcoma are allowed. Medication for the prevention of PCP (TMP/SMX, nebulized pentamidine, and atovaquone) is allowed.
- •Have peripheral neuropathy (a painful condition affecting the nervous system) or history of peripheral neuropathy.
- •Cannot take medicine by mouth or have severe chronic diarrhea within 30 days before beginning the study.
- •Cannot eat 1 or more meals a day because of chronic nausea, vomiting, or abdominal or esophageal discomfort.
- •Have had a serious illness or injury within 30 days of screening. Treatment must have been completed for 14 days prior to study entry.
- •Have a history of AIDS-defining opportunistic infection, except for tuberculosis or infection of the stomach or intestines.
研究者
研究点 (63)
Loading locations...
相似试验
已完成
3 期
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of CirrhosisHepatitis B, ChronicHepatitisCirrhosisNCT00076336Novartis Pharmaceuticals232
已完成
3 期
Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected AdultsHIV-1 InfectionNCT02345226Gilead Sciences881
已完成
3 期
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)Postoperative PainNCT00092339Merck Sharp & Dohme LLC125
已完成
不适用
A Randomized, Double-Blind, Trial Comparing Epinephrine Versus Phenylephrine as a Vasoconstrictor in Regional Anesthesia for Upper Extremity SurgeryHealthyNCT00225043New York Presbyterian Brooklyn Methodist Hospital60
终止
3 期
TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)Healthcare WorkersCOVID-19SARS-CoV 2NCT04405271Hospital Italiano de Buenos Aires1,378